This is great news and unexpected from my point of view.
This confirms PYC's business model and gives it a definitive competitive edge, assuming this process is a proprietary one and is an exclusive tie-up with PYC.
I am sure the Bio-tech journals/company watchers will have 'inside the industry' comments on this development in the coming weeks.
BTW, I have no doubts that PYC is cash stable for 2011 and will be in cash flow positive territory in 2012.
How much net revenue for the 30 mil odd MC will be a pointer to a market re-evaluation of PYC for conservative investors.
However the peptide library+business model of PYC is the real value in this company.
Short-term investors will likely gnash teeth and tear hair. It was the same for PRR in 2007-2009. I wailed and cut'n'ran.
NOT THIS TIME.
Good fortune to all, PYC watchers, holders and (bless their hearts) sellers.
PatrickM
PYC Price at posting:
7.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)